Field almanac · The four-component record
KLOW peptide research, read one star at a time
The blend has no studies of its own. Its evidence is four separate literatures — so we read each one on its own peptide, and never lend a finding to a neighbor.
Before the details
The most important fact about KLOW peptide research is what it is not: there are no KLOW studies. The blend has never been put in front of a control group. Everything below is research on one of the four peptides, done on its own — usually in cells or rats, occasionally in people. We keep each finding on the exact peptide it came from, because the most common mistake in this field is letting a strong result for one component quietly stand in for the whole mixture. Read this page as four field notebooks bound together, not as one. Where a result is for the full-length parent protein rather than the short marketed fragment — as with thymosin beta-4 versus TB-500 — we say so, because the distinction changes what the evidence actually supports.
BPC-157: tendon, ligament and angiogenesis
BPC-157 carries the deepest tissue-repair record of the four. In Wistar rats, BPC-157 accelerated healing of a fully transected Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte (tendon-cell) outgrowth in culture; doses of 10 μg, 10 ng or 10 pg per rat were tested by intraperitoneal injection [2]. At the cellular level, BPC-157 enhanced tendon-fibroblast outgrowth, survival and migration through the FAK-paxillin signaling pathway [12]. It also improved transected medial collateral ligament healing in rats [11] and promoted tendon-to-bone healing after Achilles detachment, even opposing the impairment caused by corticosteroids [8].
The angiogenic mechanism is the lens this almanac leads with. BPC-157 up-regulates VEGFR2 (the receptor that drives new blood-vessel growth) and promotes its internalization, activating the downstream VEGFR2-Akt-eNOS pathway; across chick membrane, rat hindlimb-ischemia and human endothelial-cell models this increased vessel density and accelerated blood-flow recovery, with the effect blocked when endocytosis was inhibited [6]. Human data remain thin: a retrospective case series of 16 patients reported that intra-articular BPC-157 relieved multiple types of knee pain, with 11 of 12 on BPC-157 alone improving [13], and a 2025 first-in-human IV safety pilot found intravenous BPC-157 up to 20 mg well tolerated in two healthy adults [19].
GHK-Cu: matrix synthesis and broad gene expression
GHK-Cu's evidence runs from the molecular to the clinical, and unusually for this set, much of it is human. The copper tripeptide stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin; plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and in a comparison review, topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid [4].
The gene-expression data are the broadest claim. GHK modulates expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, raising expression of 59% of affected genes and suppressing 41%, with strong stimulation of the ubiquitin-proteasome system and of DNA-repair and antioxidant gene sets [5]. (The often-quoted "~4,000 genes" figure is an extrapolation; the table at the stated threshold reports on the order of 2,100 genes.) Copper-tripeptide complexes also stimulated hair-follicle activity in C3H mice [7], and a close analog, AHK-Cu, was anti-apoptotic and pro-proliferative in human dermal papilla cells ex vivo — cited only as analog context, never as GHK-Cu efficacy [9].
TB-500, thymosin beta-4, and KPV
TB-500 is the marketed N-acetylated heptapeptide (Ac-LKKTET-Q); most of the foundational efficacy data are for the full-length 43-amino-acid parent protein, thymosin beta-4, and that distinction matters. Thymosin beta-4 accelerated wound healing in a rat full-thickness model — raising re-epithelialization 42% at four days and up to 61% at seven days, increasing wound contraction and collagen, with as little as 10 pg stimulating keratinocyte migration two- to three-fold [1] — and induced hair growth via stem-cell migration and differentiation [10]. The LKKTET motif shared by the fragment sequesters G-actin, a step linked to cell migration; integrin-linked-kinase activation and progenitor mobilization, though, are established for the native protein, not the fragment.
KPV, the C-terminal tripeptide of alpha-MSH, is carried into intestinal epithelial cells by the PepT1 di/tripeptide transporter; nanomolar KPV inhibited NF-kB and MAP-kinase inflammatory signaling and reduced pro-inflammatory cytokine secretion, and oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice [3]. Its anti-inflammatory action appears distinct from the core MSH peptides and is more likely directed at IL-1beta function than at melanocortin receptors [18].